|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000130414 |
Summary for NDUFA10 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000130414 | Gene symbol | NDUFA10 |
| Gene name | NADH:ubiquinone oxidoreductase subunit A10 | |
| HGNC | 7684 | |
| Entrez ID | 4705 | |
| Gene type | protein_coding | |
| Synonyms | NDUFA10|CI-42k | |
| UniProtAcc | O95299 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for NDUFA10 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for NDUFA10 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for NDUFA10 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUSC | cg12807937 | chr2:240026503 | CGI:chr2:240024861-240025854 | promoter | 5.32e-01 | 7.91e-01 | -3.18e+00 | 1.48e-03 | 3.38e-03 | -2.60e-01 |
| COAD | cg12807937 | chr2:240026503 | CGI:chr2:240024861-240025854 | promoter | 3.29e-01 | 4.30e-01 | -2.33e+00 | 1.99e-02 | 2.46e-02 | -1.01e-01 |
| BLCA | cg12807937 | chr2:240026503 | CGI:chr2:240024861-240025854 | promoter | 5.42e-01 | 8.04e-01 | -3.03e+00 | 2.47e-03 | 4.64e-03 | -2.62e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
Top |
Exon skipping events with PSI in TCGA for NDUFA10 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for NDUFA10 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for NDUFA10 |
| TFs related to NDUFA10. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| UVM | ZNF418 | NDUFA10 | 5.06e+00 | 9.91e-01 | 3.01e+00 | 2.04e-03 | Male-biased |
| NDUFA10 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for NDUFA10 |
| RBPs related to ES in NDUFA10. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| LUAD | ESRP2 | exon_skip_347665 | 8.10e+00 | 8.74e-03 | 8.44e+00 | 9.84e-01 | Female-biased |
| LUAD | PABPC3 | exon_skip_347685 | 1.04e+01 | 9.93e-01 | 1.00e+01 | 5.53e-03 | Male-biased |
| KIRP | ESRP2 | exon_skip_347665 | 8.66e+00 | 9.87e-01 | 8.31e+00 | 7.32e-03 | Male-biased |
| ESCA | ESRP2 | exon_skip_347665 | 8.23e+00 | 3.81e-03 | 8.80e+00 | 9.91e-01 | Female-biased |
| ESCA | PABPC3 | exon_skip_347685 | 9.89e+00 | 1.76e-02 | 1.03e+01 | 9.81e-01 | Female-biased |
| READ | PABPC3 | exon_skip_347685 | 1.00e+01 | 1.16e-02 | 1.04e+01 | 9.87e-01 | Female-biased |
| MESO | PABPC3 | exon_skip_347685 | 1.01e+01 | 1.67e-02 | 1.04e+01 | 9.82e-01 | Female-biased |
| KICH | PABPC3 | exon_skip_347685 | 9.97e+00 | 2.71e-03 | 1.04e+01 | 9.96e-01 | Female-biased |
| HNSC | ESRP2 | exon_skip_347665 | 8.59e+00 | 9.84e-01 | 8.24e+00 | 9.94e-03 | Male-biased |
| NDUFA10 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs13002508 | chr2:236589213:C:T | - | 0.199195670314889 | 0.0170269486403829 | READ | Female-baised eQTL |
| rs35353865 | chr2:236590630:G:C | - | 0.199195670314889 | 0.0170269486403829 | READ | Female-baised eQTL |
| rs34826828 | chr2:236591413:G:A | - | 0.199195670314889 | 0.0170269486403829 | READ | Female-baised eQTL |
| rs35554987 | chr2:236597283:T:C | - | 0.199195670314889 | 0.0170269486403829 | READ | Female-baised eQTL |
| rs76365399 | chr2:236599803:G:A | - | 0.199195670314889 | 0.0170269486403829 | READ | Female-baised eQTL |
| rs55941889 | chr2:238051909:T:C | - | 0.136579972789764 | 8.04060336959911e-05 | SARC | Female-baised eQTL |
| rs72983136 | chr2:238075125:G:A | - | 0.101980792067609 | 0.00452150608601743 | SARC | Female-baised eQTL |
| rs76807023 | chr2:238067026:C:T | - | 0.101821220305882 | 0.00478659633629022 | SARC | Female-baised eQTL |
| rs11678642 | chr2:238088184:G:A | - | 0.0957395193212691 | 0.00991322941191022 | SARC | Female-baised eQTL |
| rs56379553 | chr2:238089675:C:T | - | 0.0914282234993651 | 0.0151442357433621 | SARC | Female-baised eQTL |
| rs11899347 | chr2:238040975:G:A | - | 0.0866199320355744 | 0.0200489180332326 | SARC | Female-baised eQTL |
| rs59894346 | chr2:238049769:T:A | - | 0.0857050016602909 | 0.0236673260219928 | SARC | Female-baised eQTL |
| rs7563804 | chr2:238037969:C:G | - | 0.0815462216530257 | 0.0361820798068453 | SARC | Female-baised eQTL |
| rs80221317 | chr2:238065219:C:T | - | 0.0821661715099756 | 0.0363482778850579 | SARC | Female-baised eQTL |
| rs10933424 | chr2:233007698:T:C | - | 0.242038714631207 | 0.00396290584376777 | KIRP | Female-baised eQTL |
| rs6750171 | chr2:230932834:C:T | - | 0.0790375545203686 | 0.0318086008924101 | KIRC | Female-baised eQTL |
| rs10204538 | chr2:232216873:T:C | - | 0.084952482028134 | 0.0175026049981772 | LUAD | Female-baised eQTL |
| rs11890255 | chr2:237525962:A:G | - | 0.0501768711094608 | 0.0425793869923996 | LUAD | Female-baised eQTL |
| rs28397262 | chr2:235171356:C:T | - | 0.0590126740943891 | 0.0466053100852348 | LUAD | Female-baised eQTL |
| rs111339512 | chr2:237521808:G:A | - | 0.0522969715837361 | 0.0483884940191605 | LUAD | Female-baised eQTL |
| rs113280486 | chr2:237521811:G:C | - | 0.0522969715837361 | 0.0483884940191605 | LUAD | Female-baised eQTL |
| rs60604278 | chr2:237521828:G:C | - | 0.0522969715837361 | 0.0483884940191605 | LUAD | Female-baised eQTL |
| rs74001391 | chr2:237521833:G:A | - | 0.0522969715837361 | 0.0483884940191605 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs13431103 | chr2:236752316:G:A | - | -0.107700789130961 | 0.0204511960043385 | BLCA | Male-baised eQTL |
| rs11681518 | chr2:238727629:C:G | - | 0.0661349496012314 | 0.000183764166725806 | LUAD | Male-baised eQTL |
| rs116141103 | chr2:239597654:T:C | - | 0.0485926191152515 | 0.00539413249816987 | LUAD | Male-baised eQTL |
| rs35862416 | chr2:234304237:G:A | - | 0.0429956980496613 | 0.012783245289987 | LUAD | Male-baised eQTL |
| rs34115968 | chr2:234304830:C:T | - | 0.0429956980496613 | 0.012783245289987 | LUAD | Male-baised eQTL |
| rs34308241 | chr2:234304957:A:C | - | 0.0429956980496613 | 0.012783245289987 | LUAD | Male-baised eQTL |
| rs71423631 | chr2:234305355:A:G | - | 0.0429956980496613 | 0.012783245289987 | LUAD | Male-baised eQTL |
| rs36018891 | chr2:234306223:T:C | - | 0.0429956980496613 | 0.012783245289987 | LUAD | Male-baised eQTL |
| rs13001243 | chr2:234306004:G:A | - | 0.0389426218073683 | 0.0267981433196724 | LUAD | Male-baised eQTL |
| rs6431597 | chr2:238502702:G:C | - | 0.0368517455260608 | 0.0485836373903464 | LUAD | Male-baised eQTL |
| rs838705 | chr2:233364596:G:A | - | -0.0526576490765129 | 0.0430139533244921 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000130414 |
| CpG Site: cg17992259 | |
| Position to Gene: gene | |
| Male Effect: -0.490639711456161 | |
| Female Effect: - | |
 | Gene ID: ENSG00000130414 |
| CpG Site: cg19093890 | |
| Position to Gene: gene | |
| Male Effect: -0.0969334988401362 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg17992259 | chr2:239905643 | gene | -0.490639711456161 | 1.75455060181605e-193 | -0.9916431726851963 | 1.5181557458879376e-198 | LUAD |
| cg19093890 | chr2:239928767 | gene | -0.0969334988401362 | 8.91100359471025e-09 | -0.4359561833322801 | 9.247853147770354e-12 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of NDUFA10 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
